When Rodents Aren’t Enough: How Translational Pig Models Reduce Late-Stage Risk
Drug development rarely fails because a compound lacked activity. More often, it fails because preclinical models failed to predict clinical reality.
Drug development rarely fails because a compound lacked activity. More often, it fails because preclinical models failed to predict clinical reality.
Toxicology is a defining step between exploratory research and clinical development. As programs move toward IND-enabling requirements, the need for...
Experimental autoimmune encephalomyelitis (EAE) is one of the most widely used and well-characterized models for studying multiple sclerosis (MS)....
Developing effective therapeutics for pain requires selecting endpoints that accurately reflect the biological, functional, and neurophysiological...
At this year’s Society for Neuroscience (SfN) meeting, our team presented a poster highlighting the advantages of using a porcine model to bridge the...
At the forefront of translational large-animal research, our team has developed clinically relevant pig models to study nerve injury and pain....
MD Biosciences has signed the Marseille Declaration, the first joint pharmaceutical industry statement on animal housing and use. By signing, we...
Spinal cord injury (SCI) remains one of the most challenging neurological conditions to treat, with few therapies successfully translating from the...
Bridging the gap between preclinical and clinical research remains one of the most pressing challenges in drug development. While early-stage studies...